Breast cancer accounts for 22% of all cancers diagnosed in women worldwide with the risk of developing breast cancer increasing with age.
Breast cancer is a heterogeneous disease with tumors expressing a variety of aberrant proteins. Current blood tests that identify circulating tumor antigens are elevated most commonly in patients with metastatic disease and appear to reflect tumor bulk. They are too insensitive to be used for the screening and early diagnosis of primary breast cancers.
Autoantibodies produced against such tumor-associated antigens may provide an in vivo amplification of an early carcinogenic signal and therefore may allow earlier detection of cancer than current methods allow. 
DISCUSSION
This study demonstrates that an autoantibody panel ELISA system can be used to reproducibly identify 64% of women with early invasive primary breast cancer, and 45% of women with DCIS, independent of the clinical or histological features of the tumor.
Autoantibody assays may have a significant role to play in the future of early breast cancer diagnosis. 
